Cubist Pharmaceuticals, Inc. (CBST)

[surf1944]

September 12-15
Infectious-disease experts will be congregating in Boston for the International Conference of Antimicrobial Agents and Chemotherapy annual meeting. Investors of Cubist Pharmaceuticals (CBST) should be watching out for further data on CXA-101, a drug the company acquired last year. A glimpse of top-line results for the treatment of complicated urinary tract infections was released in June, but the company will be expanding on what looks like positive results. This is important to Cubist’s CXA-201 program, which is a combination of CXA-101 and another agent. The company has recently begun a mid-stage study for CXA-201.

http://www.minyanville.com/businessmarkets/articles/biotech-pharmaceuticals-obesity-diabetes-advisory-committee/9/1/2010/id/29903?camp=syndication&medium=portals&from=yahoo